Home Print this page Email this page Small font size Default font size Increase font size
Users Online: 79
Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 

 Table of Contents  
Year : 2013  |  Volume : 27  |  Issue : 2  |  Page : 143-146

A case of bronchial asthma and allergic rhinitis exacerbated during Cannabis pollination and subsequently controlled by subcutaneous immunotherapy

Department of Respiratory Allergy and Applied Immunology, National Centre of Respiratory Allergy, Asthma and Immunology, Vallabhbhai Patel Chest Institute, University of Delhi, Delhi, India

Date of Web Publication4-Jan-2014

Correspondence Address:
Raj Kumar
Department of Respiratory Allergy and Applied Immunology, National Centre of Respiratory Allergy, Asthma and Immunology, Vallabhbhai Patel Chest Institute, University of Delhi, Delhi - 110 007
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/0972-6691.124399

Rights and Permissions

The prevalence of bronchial asthma and allergic rhinitis has been on the rise in India. Cannabis is reported to be one of the allergenically important airborne pollen identified by the clinico-immunologic evaluation in the spring season in India. We report a case of 38-year-old male patient with typical clinical manifestations of bronchial asthma and allergic rhinitis that classically exacerbates during the pollination period of Cannabis. On evaluation, the patient was found to be significantly sensitized to Cannabis sativa. Subsequent subcutaneous immunotherapy leads to marked improvement in control of asthma as well as improved quality-of-life.

Keywords: Allergic rhinitis, bronchial asthma, Cannabis sativa, subcutaneous immunotherapy

How to cite this article:
Kumar R, Gupta N. A case of bronchial asthma and allergic rhinitis exacerbated during Cannabis pollination and subsequently controlled by subcutaneous immunotherapy. Indian J Allergy Asthma Immunol 2013;27:143-6

How to cite this URL:
Kumar R, Gupta N. A case of bronchial asthma and allergic rhinitis exacerbated during Cannabis pollination and subsequently controlled by subcutaneous immunotherapy. Indian J Allergy Asthma Immunol [serial online] 2013 [cited 2023 Feb 3];27:143-6. Available from: https://www.ijaai.in/text.asp?2013/27/2/143/124399

  Introduction Top

The prevalence of allergic diseases such as bronchial asthma and allergic rhinitis has been on the rise all over the world including developing countries like India. The number of people suffering from allergy is 20% to 30% of population and pollinosis alone accounts in about 10-15% of the world inhabitants. [1],[2],[3]

Hemp (Cannabis sativa), a plant of Asian origin belongs to Cannabaceae family. It is usually cultivated but may grow wild in some places. C. sativa is, an anemophilous plant bears very light pollen which can be transported over long distances and its allergenic capability varying from being mild to high. [4] In an analysis of the qualitative and quantitative prevalence of pollen allergens from India, Cannabis was reported to be one of the allergenically important airborne pollen identified by the clinico-immunologic evaluation in the spring season (February-April). [5]

In a recent retrospective analysis of skin prick testing (SPT) in 918 patients suffering from bronchial asthma and/or allergic rhinitis, Cannabis was found to be offending allergen in 2.18% cases. [6] Stokes et al. [7] evaluated the patients complaining of asthma and/or rhinitis symptoms on exposure to Cannabis plants during the summer and concluded Cannabis skin test positive patients demonstrates typical symptoms of allergic respiratory disorders during pollination periods. A review of the literature revealed though the allergic potential of Cannabis being documented for more than 60 years, yet the studies indicating clinical significance of its pollen as an aeroallergen and its management has been sparse.

  Case Report Top

The present case report is about a 38-year-old human immunodeficiency virus negative male doctor, current smoker who presented to our Institute for evaluation of episodic breathlessness accompanied with wheeze which he had been suffering for a period of 18 years. These episodes were associated with sneezing, rhinorrhea and nasal itching. The symptoms had characteristic worsening during the spring season (February-April). General physical examination revealed no pallor, clubbing or cyanosis. He was tachypneic with a respiratory rate of 26/min. On auscultation, vesicular breath sounds of equal intensity were audible bilaterally along with rhonchi. On serological investigation, hemoglobin 12.07 g/dl, white blood cell count 8900/μl, eosinophil 7%. The radiology was within the normal limits.

At presentation, patient has been on inhaled corticosteroid and long acting beta-2 agonist combination therapy for last 8 years and was compliant, but requires additional oral corticosteroid therapy frequently for control of his symptoms. Patient also has to take frequent doses of oral anti-histamines to control the nasal symptoms.

The history of the patient was suggestive of uncontrolled bronchial asthma with allergic rhinitis, with worsening during the spring season. The family history was negative for atopy. On evaluation, patient was found to have symptom aggravation during the spring season while having his morning walk through the open spaces near his home. On the other hand, the symptoms are of lesser intensity on avoidance of that zone. On geographical survey, rich flora of C. sativa was observed in the surrounding locale. Patient also denied any history of smoking marijuana. Patient underwent SPT, the reaction was significantly positive (4+) with pseudopodia formation against C. sativa [Figure 1]. Subsequently subcutaneous perennial immunotherapy (IT) versus C. sativa was initiated with 1:5000 w/v diluted antigen and the injections were given 2 times a week starting from 0.1 ml and increased in every injection by 0.1 ml. The further schedule is labeled in [Table 1]. [8] After a maintenance dose of 1 year, patient had a well-controlled asthma and rhinitis and is currently following up on a maintenance dose. The patient reports of having resumed his march through the same area devoid of episodes of exacerbations.
Figure 1: Skin prick testing showing the reaction was significantly positive (4+) with pseudopodia formation against Cannabis sativa

Click here to view
Table 1: Immunotherapy schedule of the patient

Click here to view

  Discussion Top

The earliest evidence of potential allergenicity of Cannabis pollen comes from a case report of a female physician, from Omaha who developed symptoms of rhino-conjunctivitis while marching near pollinating plants. Subsequently, on SPT with hemp pollen she developed an anaphylactic reaction. [9] Anaphylactic response, in a 29-year-old female smoking marijuana cigarette for the first time, was documented in 1971 and further confirmed by SPT and passive transfer studies. It was suggested that tetrahydrocannabinol was accountable for immunological response.

Since then, isolated cases of allergic hypersensitivity to C. sativa have been described, urticaria and contact dermatitis due to handling of Cannabis plants [10],[11] and anaphylaxis due to Cannabis ingestion. [12] Paradoxically, the protective action of Cannabis against allergies has also been described. [13]

The study by Stokes et al. [7] hypothesized that Cannabis might be clinically important allergen especially in patients complaining of asthma and/or rhinitis symptoms. The hemp pollen accounted for 36% of the total pollen count. In a sample of pollen-allergic patients, 78% were sensitive to C. sativa pollen and 73% presented symptoms during the pollination season. Thus a strong association was observed between skin test reactivity, respiratory symptoms and pollination period. However, since the patients also had concomitant sensitization, the authors proposed further additional studies. Our patient also had a significant skin test reactivity correlating both with worsening of symptoms as well as the pollinating season, thus demonstrating Cannabis allergic sensitization.

In a cohort of 17 individuals with symptoms suggestive of marijuana sensitivity, 15 were suffered from rhinitis and conjunctivitis on inhalational exposure. [14] Other manifestations were urticaria, periorbital angioedema, wheezing and sinusitis. All individuals reported symptoms on repeated exposures and cessation following avoidance of marijuana. In current case, the patient too had aggravation of symptoms on repeated exposures and reduced intensity on avoidance of allergen.

The identification of five C. sativa IgE-binding proteins, ranging from 10 to 68 kDa and a 9-kDa lipid transfer protein have been implicated with type 1 sensitization to Cannabis plant. In Cannabis sensitized patients cross-reactivity has been observed with tomato, tobacco, latex, ragweed, pigweed and Aspergillus. [15],[16],[17] In our case, the SPT was performed against 58 aero-allergens including Aspergillus but only Cannabis was positive.

Allergen specific immunotherapy works through enhancing immune tolerance mechanisms and reduction in the lymphoproliferative responses to allergens. It is the most effective therapeutic approach for dysregulated immune response toward allergens and shifting of immune response from the allergic Th2 to non-allergic Th1. [18]

IT has been highly effective in management of allergic rhinitis, allergic conjunctivitis, allergic asthma and stinging insect hypersensitivity. [19],[20] In a study by Gaur et al. [21] half of patients suffering from seasonal allergic rhinitis exhibited substantial reduction in their symptom score as well as drug intake after 2 years of IT with mixed allergen vaccines. A study comparing inhaled budesonide with IT in subjects of perennial asthma; IT resulted in slow but steady improvement which was long lasting and did not decline rapidly in comparison to budesonide therapy. [22] In another prospective study of subjects suffering from asthma and rhinitis IT showed significant improvement in the symptom score, forced expiratory volume in first second, and immunological parameters. [23],[24] Similar to results above, our case also showed slow, steady and sustained response to IT with marked improvement in his symptoms, quality-of-life and significant reduction of his drugs dosages. To the best of our knowledge, this is the unique study in which IT against Cannabis has been initiated and the response being documented.

The above case attempts to highlights the importance of familiarity with local aero-allergen prevalence and difficulty in assessing Cannabis exposure history and thus increased awareness of Cannabis as a potential aeroallergen should be nurtured. The identification of the allergen and subsequent initiation of IT with dramatic response to symptoms and quality-of-life in the current case may denote a role of IT in management of Cannabis allergy.

  References Top

1.Pekkanen J, Remes ST, Husman T, Lindberg M, Kajosaari M, Koivikko A, et al. Prevalence of asthma symptoms in video and written questionnaires among children in four regions of Finland. Eur Respir J 1997;10:1787-94.  Back to cited text no. 1
2.Woolcock AJ, Bastiampillai SA, Marks GB, Keena VA. The burden of asthma in Australia. Med J Aust 2001;175:141-5.  Back to cited text no. 2
3.Anthracopoulos M, Karatza A, Liolios E, Triga M, Triantou K, Priftis K. Prevalence of asthma among schoolchildren in Patras, Greece: Three surveys over 20 years. Thorax 2001;56:569-71.  Back to cited text no. 3
4.Mayoral M, Calderón H, Cano R, Lombardero M. Allergic rhinoconjunctivitis caused by Cannabis sativa pollen. J Investig Allergol Clin Immunol 2008;18:73-4.  Back to cited text no. 4
5.Singh AB, Shahi S. Aeroallergens in clinical practice of allergy in India- ARIA Asia Pacific Workshop report. Asian Pac J Allergy Immunol 2008;26:245-56.  Back to cited text no. 5
6.Kumar R, Sharan N, Kumar M, Bisht I, Gaur SN. Pattern of skin sensitivity to various aeroallergens in patients of bronchial asthma and/or allergic rhinitis in India. Indian J Allergy Asthma Immunol 2012;26:66-72.  Back to cited text no. 6
  Medknow Journal  
7.Stokes JR, Hartel R, Ford LB, Casale TB. Cannabis (hemp) positive skin tests and respiratory symptoms. Ann Allergy Asthma Immunol 2000;85:238-40.  Back to cited text no. 7
8.Gaur SN, Singh BP, Singh AB, Vijayan VK, Agarwal MK. Guidelines for practice of allergen immunotherapy in India. Indian J Allergy Asthma Appl Immunol 2009;23:1-20.  Back to cited text no. 8
9.Maloney ES, Brodkey MH. Hemp pollen sensitivity in Omaha. Nebr Med J 1940;25:190-1.  Back to cited text no. 9
10.Williams C, Thompstone J, Wilkinson M. Work-related contact urticaria to Cannabis sativa. Contact Dermatitis 2008;58:62-3.  Back to cited text no. 10
11.Majmudar V, Azam NA, Finch T. Contact urticaria to Cannabis sativa. Contact Dermatitis 2006;54:127.  Back to cited text no. 11
12.Stadtmauer G, Beyer K, Bardina L, Sicherer SH. Anaphylaxis to ingestion of hempseed (Cannabis sativa). J Allergy Clin Immunol 2003;112:216-7.  Back to cited text no. 12
13.Clement YN, Williams AF, Aranda D, Chase R, Watson N, Mohammed R, et al. Medicinal herb use among asthmatic patients attending a specialty care facility in Trinidad. BMC Complement Altern Med 2005;5:3.  Back to cited text no. 13
14.Tessmer A, Berlin N, Sussman G, Leader N, Chung EC, Beezhold D. Hypersensitivity reactions to marijuana. Ann Allergy Asthma Immunol 2012;108:282-4.  Back to cited text no. 14
15.de Larramendi CH, Carnés J, García-Abujeta JL, García-Endrino A, Muñoz-Palomino E, Huertas AJ, et al. Sensitization and allergy to Cannabis sativa leaves in a population of tomato (Lycopersicon esculentum)-sensitized patients. Int Arch Allergy Immunol 2008;146:195-202.  Back to cited text no. 15
16.Armentia A, Dueñas-Laita A, Bartolomé B, Martín-Gil FJ, San Miguel A, Castrodeza JJ. Clinical significance of cross-reactivity between tobacco and latex. Allergol Immunopathol (Madr) 2010;38:187-96.  Back to cited text no. 16
17.Kagen SL. Aspergillus: An inhalable contaminant of marihuana. N Engl J Med 1981;304:483-4.  Back to cited text no. 17
18.Akdis M, Akdis CA. Mechanism of allergen-specific immunotherapy. J Allergy Clin Immunol 2007;119:780-9.  Back to cited text no. 18
19.Cox L, Nelson H, Lockey R, Calabria C, Chacko T, Finegold I, et al. Allergen immunotherapy: A practice parameter third update. J Allergy Clin Immunol 2011;127:S1-55.  Back to cited text no. 19
20.Gaur SN, Singh AB, Mehta AK. Successful desensitization with honey bee venom: A case report. Indian J Allergy Asthma Immunol 2007;21:69-7.  Back to cited text no. 20
21.Gaur SN, Gupta SN, Gupta S. Clinical response of immunotherapy in cases of nasobronchial allergy. Indian J Allergy Asthma Immunol 1996;10:65-8.  Back to cited text no. 21
22.Shaikh WA. Immunotherapy vs inhaled budesonide in bronchial asthma: An open, parallel, comparative trial. Clin Exp Allergy 1997;27:1279-84.  Back to cited text no. 22
23.Srivastava D, Singh BP, Sudha VT, Arora N, Gaur SN. Immunotherapy with mosquito (Culex quinquefasciatus) extract: A double-blind, placebo-controlled study. Ann Allergy Asthma Immunol 2007;99:273-80.  Back to cited text no. 23
24.Srivastava D, Singh BP, Arora N, Gaur SN. Clinico-immunologic study on immunotherapy with mixed and single insect allergens. J Clin Immunol 2009;29:665-73.  Back to cited text no. 24


  [Figure 1]

  [Table 1]

This article has been cited by
1 A review of cannabis allergy in the early days of legalization
Alessandro Toscano, Didier G. Ebo, Khaldon Abbas, Hannelore Brucker, Ine I. Decuyper, David Naimi, Anil Nanda, Ajay P. Nayak, Isabel J. Skypala, Gordon Sussman, Joanna S. Zeiger, William S. Silvers
Annals of Allergy, Asthma & Immunology. 2022;
[Pubmed] | [DOI]
2 The use of Medical Cannabis Concomitantly with Immune-Check Point Inhibitors (ICI) in Non-Small Cell Lung Cancer (NSCLC): a Sigh of Relief?
Barliz Waissengrin, Yasmin Leshem, Marwa Taya, David Meiri, Ofer Merimsky, Sivan Shamai, Ido Wolf, Tami Rubinak
European Journal of Cancer. 2022;
[Pubmed] | [DOI]
3 Inhaled Marijuana and the Lung
Donald P. Tashkin, Wan-Cheng Tan
The Journal of Allergy and Clinical Immunology: In Practice. 2022;
[Pubmed] | [DOI]
4 Cannabis-related allergies: An international overview and consensus recommendations
Isabel J. Skypala, Samira Jeimy, Hannelore Brucker, Ajay P. Nayak, Ine I. Decuyper, Jonathan A. Bernstein, Lori Connors, Amin Kanani, Ludger Klimek, Shun Chi Ryan Lo, Kevin R. Murphy, Anil Nanda, Jill. A. Poole, Jolanta Walusiak-Skorupa, Gordon Sussman, Joanna S. Zeiger, Richard E. Goodman, Anne K. Ellis, William S. Silvers, Didier G. Ebo
Allergy. 2022;
[Pubmed] | [DOI]
5 Successful treatment with a combination of bee venom immunotherapy and omalizumab for recurrent anaphylaxis after honey bee sting
PC Kathuria, Manisha Rai, Ghulam Hassan
Indian Journal of Allergy, Asthma and Immunology. 2021; 35(2): 94
[Pubmed] | [DOI]
6 Surveillance of work-related asthma including the emergence of a cannabis-associated case series in Washington State
Carolyn Reeb-Whitaker,Claire R. LaSee,David K. Bonauto
Journal of Asthma. 2021; : 1
[Pubmed] | [DOI]
7 Adverse Reactions to Illicit Drugs (Marijuana, Opioids, Cocaine) and Alcohol
Ine I. Decuyper,Alicia Armentia,Blanca Martín-Armentia,Alfredo Corell Almuzara,Didier G. Ebo,Hannelore A. Brucker
The Journal of Allergy and Clinical Immunology: In Practice. 2021;
[Pubmed] | [DOI]
8 An emerging allergen: Cannabis sativa allergy in a climate of recent legalization
Bradley Jackson,Erica Cleto,Samira Jeimy
Allergy, Asthma & Clinical Immunology. 2020; 16(1)
[Pubmed] | [DOI]
9 A longitudinal study of cannabis use increasing the use of asthma medication in young Norwegian adults
Jørgen G. Bramness,Tilmann von Soest
BMC Pulmonary Medicine. 2019; 19(1)
[Pubmed] | [DOI]
10 It’s All Relative! Engaging Nursing and Exercise Science Students in Chemical Education Using Medical Case Studies
Angela L. Mahaffey
Journal of Chemical Education. 2019;
[Pubmed] | [DOI]
11 Occupational health and safety in cannabis production: an Australian perspective
Maggie Davidson,Sue Reed,Jacques Oosthuizen,Greg O’Donnell,Pragna Gaur,Martyn Cross,Gary Dennis
International Journal of Occupational and Environmental Health. 2018; : 1
[Pubmed] | [DOI]
12 Cannabis-Associated Asthma and Allergies
J. M. Chatkin,L. Zani-Silva,I. Ferreira,N. Zamel
Clinical Reviews in Allergy & Immunology. 2017;
[Pubmed] | [DOI]
13 Asthma Associated with the Use of Cocaine, Heroin, and Marijuana: A Review of the Evidence
Timothy H. Self,Samarth Shah,Katherine L. March,Christopher W. Sands
Journal of Asthma. 2016; : 00
[Pubmed] | [DOI]
14 Cannabis sativa: the unconventional “weed” allergen
Thad L. Ocampo,Tonya S. Rans
Annals of Allergy, Asthma & Immunology. 2015; 114(3): 187
[Pubmed] | [DOI]


Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
Access Statistics
Email Alert *
Add to My List *
* Registration required (free)

  In this article
Case Report
Article Figures
Article Tables

 Article Access Statistics
    PDF Downloaded125    
    Comments [Add]    
    Cited by others 14    

Recommend this journal